Acquisition of a parallel stirred-tank bioreactor system to accelerate and advance the development of next-generation probiotics

收购并行搅拌罐生物反应器系统，以加速和推进下一代益生菌的开发

• 批准号: 10389127
• 负责人: Jan-Peter van Pijkeren
• 金额: $ 11.92万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-04-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10389127
• 关键词: Adhesions; Advanced Development; Aftercare; Agriculture; Animal Model; Bacteria; Bacterial Adhesins; Bacteriophages; Biological; Biological Containment; Bioreactors; Cells; Clustered Regularly Interspaced Short Palindromic Repeats; Complex; Containment; Cytolysis; DNA; Development; Disease; Disease Management; Engineering; Environment; Epithelial Cells; Frequencies; Gastrointestinal tract structure; Gene Deletion; Genes; Genetically Modified Organisms; Goals; Gram-Negative Bacteria; Growth; Health; Human; In Situ; Lactobacillus reuteri; Measures; Mediating; Medicine; Microbe; Mission; Mucous body substance; Organism; Probiotics; Proteins; Publishing; Recombinants; Research; Safety; Sampling; Specificity; Surface; System; Therapeutic; Thymidine; Thymidylate Synthase; Time; United States National Institutes of Health; Validation; Work; auxotrophy; base; clinical application; gastrointestinal; immunoreaction; improved; in vivo; microbial; microbial community; microbiota; next generation; novel; prevent; prototype; tool

The use of synthetic microbes to deliver therapeutics offers excellent potential to manage diseases in both agriculture and human medicine. However, use of genetically modified organisms (GMOs) raises immediate concerns with regards to their containment. Therefore, strategies must be developed that prevents permanent colonization and accumulation of the GMO in the host and environment, respectively. Also, a kill-switch must be in-place to eradicate the GMO efficiently. Especially in human medicine, an efficient kill-switch is needed to overcome safety concerns when complications would occur as a consequence of an immune reaction against the therapeutic molecule. Until we have overcome these fundamental technical challenges, clinical applications of microbial therapeutics will be beyond reach in human medicine. Our long-term goal is to develop probiotic bacteria as therapeutic delivery vehicles to improve human health. The overall objective of this application is to establish containment and safety strategies which we envision will be broadly applicable in both gram-positive and gram-negative bacteria. Our central hypotheses are a.) that deletion of genes encoding adhesins will reduce the organism's ability to interact with host cells; b.) that thymidine auxotrophy will limit growth in the environment; c.) that CRISPR-delivery by recombinant bacteriophages can specifically eradicate the target organism from a complex environment. Our hypotheses have been formulated based on our published findings. We demonstrated that L. reuteri adhesins are critical to adhere to epithelial cells, that cells lacking thyA are dependent on exogenously added thymidine, that L. reuteri encodes biologically active bacteriophages in vivo, and that CRISPR-Cas is functional in L. reuteri. The rationale for the proposed research is that successful completion of this work is expected to yield a prototype of Lactobacillus reuteri that can be used for safe in situ delivery of therapeutics to treat an array of diseases with an embedded biological containment system that is broadly applicable in both Gram-negative and Gram-positive microbes. We plan to accomplish the overall objective by completing three specific aims. In Aim #1 we will develop a delivery vehicle with reduced colonization potential. In Aim #2 we will develop an environmental containment strategy based on thymidine auxotrophy. In Aim #3 we will develop recombinant phages to achieve strain-specific killing of L. reuteri via CRISPR-Cas. L. reuteri phages will be engineered to encode CRISPR arrays targeting engineered L. reuteri. Strategies will be implemented to reduce `escapers', and in vivo efficacy and specificity will be determined. When successful, our work will have a positive impact as we will have developed a functioning prototype of a safety strategy for a synthetic microbe, which we expect will serve as a novel research tool to deliver therapeutics in situ. The evolutionary conservation of thyA combined with the abundance of bacteriophages and CRISPR-Cas systems make our platform broadly applicable to both gram-positive and gram-negative bacteria.

使用合成微生物来提供治疗，为管理这两种疾病提供了极好的潜力